Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial
Thomas Bradbury,Gian Luca Di Tanna,Anish Scaria,Allison Martin,Fu-Qiang Wen,Nan-Shan Zhong,Jin-Ping Zheng,Peter J Barnes,Bartolome Celli,Norbert Berend,Christine R Jenkins
DOI: https://doi.org/10.2147/COPD.S339889
2022-02-05
International Journal of COPD
Abstract:Thomas Bradbury, 1 Gian Luca Di Tanna, 1 Anish Scaria, 1 Allison Martin, 1 Fu-Qiang Wen, 2 Nan-Shan Zhong, 3 Jin-Ping Zheng, 3 Peter J Barnes, 4 Bartolome Celli, 5 Norbert Berend, 1 Christine R Jenkins 1 On behalf of the TASCS Investigators 1 Respiratory Group, The George Institute for Global Health, Sydney, NSW 2042, Australia; 2 West China Hospital, Sichuan University, Chengdu, People's Republic of China; 3 State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 4 National Heart & Lung Institute, Imperial College, London, UK; 5 Pulmonary and Critical Care Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Correspondence: Thomas Bradbury Respiratory Group, The George Institute for Global Health, Level 5, 1 King St, Newtown, Sydney, NSW 2042, Australia , Tel +61 2 8052 4413 , Email Background and Objectives: The burden of chronic obstructive pulmonary disease (COPD) disproportionately affects patients in low to middle-income countries. Although the Theophylline and Steroids in COPD Study (TASCS) showed no clinical benefit from administering low-dose theophylline and prednisone in COPD patients compared to placebo, it was hypothesized that those with elevated blood eosinophil counts would receive clinical benefit from the intervention. Methods: This was a post-hoc analysis of the TASCS dataset – a double-blinded, placebo-controlled trial conducted in patients with moderate–severe COPD in China. Participants were allocated 1:1:1 to low-dose oral theophylline (100mg bd) and prednisone (5mg qd; PrT), theophylline (100mg bd) and prednisone-matched placebo (TP), or double-matched placebo (DP) groups and followed-up for 48 weeks. A baseline count of ≥ 300 eosinophils/μL blood was categorized as elevated/eosinophilic, and the primary outcome was the annualized moderate-severe exacerbation rate. Results: Of 1487 participants eligible for analysis, 325 (22%) were eosinophilic. These participants were predominantly male (82%), had a mean (SD) age of 64 (± 8) years and a predicted forced expiratory volume in 1s (FEV 1 ) of 43% (± 16). The annualized moderate–severe exacerbation rate was significantly higher in the PrT group compared to the pooled results of the TP and DP groups (incidence rate ratio = 1.6; ([95% CI 1.06– 1.76]) p = 0.016). Changes in spirometry values and reported disease impact scores (St. George's Respiratory Questionnaire and COPD Assessment Test) at week 48 were not significantly different between groups. Conclusion: Combination low-dose theophylline and prednisone was associated with a significant increase in the annual moderate-severe exacerbation rate in participants with a blood eosinophil count ≥ 300 cells/μL compared to placebo. Keywords: eosinophil, COPD, clinical trial, China, theophylline, prednisone Chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality worldwide, with an estimated prevalence of approximately 3% of the global community in 2019. 1 Current guidelines recommend use of long-acting bronchodilators to reduce symptoms and exacerbations, with the addition of inhaled corticosteroids when exacerbations become more frequent, particularly if blood eosinophil counts are raised above 300 cells/μL. 2 For significant portions of the global patient population, these pharmacotherapies are often under-utilized due to limited access and affordability – necessitating the use of low-cost alternatives where available. Previous in vitro and in vivo studies had suggested that the activity of histone deacetylase-2 (HDAC2), a nuclear enzyme that inhibits inflammatory gene expression, is markedly reduced in COPD. By interfering with the anti-inflammatory effects of corticosteroids, HDAC2 can be increased by low concentrations of theophylline, restoring corticosteroid responsiveness. 3–6 Thus, it was hypothesized that theophylline could promote anti-inflammatory gene expression and restore sensitivity to glucocorticosteroids in COPD patients, hence improving their response to prednisone. In the absence of access to gold standard bronchodilator therapy, this pharmacologic synergism could potentially provide an affordable and highly accessible management strategy for COPD patients in resource-poor settings. The "Theophylline And Steroids in COPD Study" (TASCS) was a multicenter randomized control trial undertaken in China to determine if the effect observed in vitro translated into cli -Abstract Truncated-